The first-generation reversible anti-EGFR tyrosine kinase inhibitors erlotinib and gefitinib were initially approved as second-line therapies in advanced patients after chemotherapy based on the many clinical trials that demonstrated their efficacy in some patients after initial lines of chemotherapy.76–80 They are now recommended as first-line therapies in advanced lung cancer patients with EGFR mutations. This evidence concerns the gene EGFR and lung carcinoma.